Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:NYXH

Nyxoah Q1 2026 Earnings Report

Nyxoah logo
$2.97 +0.09 (+3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$2.97 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nyxoah EPS Results

Actual EPS
N/A
Consensus EPS
-$0.54
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q1 2026
Date
5/12/2026
Time
Before Market Opens
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Nyxoah Earnings Headlines

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference
April 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nyxoah-to-participate-in-the-bank-of-america-2026-healthcare-conference-1036089464
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3283163/0/en/nyxoah-to-release-first-quarter-2026-financial-results-on-may-12-2026.html
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
May 5 at 1:00 AM  |  American Alternative (Ad)
Nyxoah (NYXH) price target decreased by 12.79% to 9.82
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/nyxoah-nyxh-price-target-decreased-by-12-79-to-9-82/ar-AA211CgF
Baird Lowers its Price Target on Nyxoah SA (NYXH) to $4.62 from $5.87
April 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/baird-lowers-price-target-nyxoah-121630140.html
Baird Lowers its Price Target on Nyxoah SA (NYXH) to $4.62 from $5.87
April 4, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/baird-lowers-its-price-target-on-nyxoah-sa-nyxh-to-4-62-from-5-87-1732093/
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy.

Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.

View Nyxoah Profile
Earnings Tools